Infection Control News

A two-dose series of a hepatitis B vaccine with a CpG adjuvant resulted in a more than 90% response rate among health care workers previously classified as nonresponders, researchers found.

When it comes to screening perinatally exposed infants for hepatitis C virus, the earlier the better, a study showed.

Together, a group of viruses nicknamed “FLiRT” have emerged to become the most common SARS-CoV-2 variants in the country.

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.

An AI system correctly chose antibiotics for sepsis treatment faster than the standard method using blood cultures, according to a study presented at ASM Microbe.

The leading U.S. professional association for infection preventionists recently called for an overhaul to medical device cleaning instructions based on a survey that revealed confusion, inconsistency and potential danger.

SAN ANTONIO — At this year’s Association for Professionals in Infection Control and Epidemiology annual conference, the program’s keynote talks focused on developing both skills and confidence, and consciously leading infection prevention efforts.

Moderna announced positive phase 3 trial data for its combination COVID-19 and influenza vaccine this week, suggesting a combination shot for respiratory infections is on the way.

COVID-19 mitigation measures disrupted the circulation of respiratory syncytial virus, leading to atypical season in 2021 and 2022 that saw higher rates of hospitalization among young children, according to research published in Pediatrics.

In late May, the FDA announced approval of Moderna's mResvia, marking the third vaccine approved for respiratory syncytial virus and first time messenger RNA technology has been used for preventing a disease other than COVID-19.